N-(benzyloxy)cyclohexanecarboxamide | 172847-66-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(benzyloxy)cyclohexanecarboxamide
• 英文别名: N-benzyloxycyclohexanecarboxamide；O-Benzylcyclohexyl hydroxamate；N-phenylmethoxycyclohexanecarboxamide
• CAS: 172847-66-4
• 化学式: C₁₄H₁₉NO₂
• mdl: MFCD02280218
• 分子量: 233.31
• InChiKey: OKFYBNPULQFGII-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(benzyloxy)cyclohexanecarboxamide 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 以99%的产率得到环己烷羧肟酸
  参考文献：
  名称：

  A Convenient Procedure for the Preparation of Amino Acid Hydroxamates from Esters

  摘要：

  DOI：

  10.1021/jo00129a059
• 作为产物：
  描述：

  环己甲酸甲酯 、 苄氧基胺盐酸盐 在 三甲基铝 作用下， 生成 N-(benzyloxy)cyclohexanecarboxamide
  参考文献：
  名称：

  A Convenient Procedure for the Preparation of Amino Acid Hydroxamates from Esters

  摘要：

  DOI：

  10.1021/jo00129a059

文献信息

• [EN] COMPOUNDS FOR INHIBITING 1- DEOXY-D-XYLULOSE- 5 - PHOSPHATE REDUCTOISOMERASE<br/>[FR] COMPOSÉS DESTINÉS À INHIBER LA 1-DÉSOXY-D-XYLULOSE-5-PHOSPHATE RÉDUCTOISOMÉRASE
  申请人：UNIV GEORGE WASHINGTON

  公开号：WO2013006444A1

  公开（公告）日：2013-01-10

  [0082] In particular, the compound is effective to inhibit Dxr in Mycobacterium tuberculosis (Mtb). The present invention relates to compounds having general formula (I) or where X is an acidic group, such as carboxylate, phosphonate, sulfate, and tetrazole; Ar is a substituted or unsubstituted aromatic or heteroaromatic group; and n is 0, 1, 2, 3, or 4, preferably 2, 3, or 4. The compounds inhibits l-deoxy-D-xylulose-5-phosphate reductoisomerase (Dxr), particularly Dxr in Mycobacterium tuberculosis (Mtb).

  特别是，该化合物能有效抑制结核分枝杆菌（Mtb）中的Dxr。本发明涉及具有通式（I）的化合物，其中X是酸性基团，如羧酸盐、膦酸盐、硫酸盐和四唑基；Ar是取代或未取代的芳香或杂环芳基团；n为0、1、2、3或4，优选为2、3或4。这些化合物抑制l-脱氧-D-木糖-5-磷酸还原异构酶（Dxr），特别是结核分枝杆菌（Mtb）中的Dxr。
• Compounds for inhibiting 1-deoxy-D-xylulose-5-phosphate reductoisomerase
  申请人：Boshoff Helena I.

  公开号：US09593136B2

  公开（公告）日：2017-03-14

  In particular, the compound is effective to inhibit Dxr in Mycobacterium tuberculosis (Mtb). The present invention relates to compounds having general formula (I) or (II) where X is an acidic group, such as carboxylate, phosphonate, sulfate, and tetrazole; Ar is a substituted or unsubstituted aromatic or heteroaromatic group; and n is 0, 1, 2, 3, or 4, preferably 2, 3, or 4. The compounds inhibits 1-deoxy-D-xylulose-5-phosphate reductoisomerase (Dxr), particularly Dxr in Mycobacterium tuberculosis (Mtb).

  特别是，该化合物能有效抑制结核分枝杆菌（Mtb）中的Dxr。本发明涉及具有一般式（I）或（II）的化合物 其中X是酸性基团，如羧酸盐、膦酸盐、硫酸盐和四唑基；Ar是取代或未取代的芳香或杂芳基团；n为0、1、2、3或4，优选为2、3或4。这些化合物抑制1-脱氧-D-木糖-5-磷酸还原异构酶（Dxr），特别是结核分枝杆菌（Mtb）中的Dxr。
• Design of potential bisubstrate inhibitors against Mycobacterium tuberculosis (Mtb) 1-deoxy-d-xylulose 5-phosphate reductoisomerase (Dxr)—evidence of a novel binding mode
  作者：Géraldine San Jose、Emily R. Jackson、Eugene Uh、Chinchu Johny、Amanda Haymond、Lindsay Lundberg、Chelsea Pinkham、Kylene Kehn-Hall、Helena I. Boshoff、Robin D. Couch、Cynthia S. Dowd

  DOI：10.1039/c3md00085k

  日期：——

  In most bacteria, the nonmevalonate pathway is used to synthesize isoprene units. Dxr, the second step in the pathway, catalyzes the NADPH-dependent reductive isomerization of 1-deoxy-D-xylulose-5-phosphate (DXP) to 2-C-methyl-D-erythritol-4-phosphate (MEP). Dxr is inhibited by natural products fosmidomycin and FR900098, which bind in the DXP binding site. These compounds, while potent inhibitors of Dxr, lack whole cell activity against Mycobacterium tuberculosis (Mtb) due to their polarity. Our goal was to use the Mtb Dxr-fosmidomycin co-crystal structure to design bisubstrate ligands to bind to both the DXP and NADPH sites. Such compounds would be expected to demonstrate improved whole cell activity due to increased lipophilicity. Two series of compounds were designed and synthesized. Compounds from both series inhibited Mtb Dxr. The most potent compound (8) has an IC50 of 17.8 μM. Analysis shows 8 binds to Mtb Dxr via a novel, non-bisubstrate mechanism. Further, the diethyl ester of 8 inhibits Mtb growth making this class of compounds interesting lead molecules in the search for new antitubercular agents.

  在大多数细菌中，非梅瓦隆酸途径用于合成异构烯单位。该途径的第二步是Dxr，它催化NADPH依赖的1-脱氧-D-木酮糖-5-磷酸（DXP）转化为2-C-甲基-D-赤藓糖-4-磷酸（MEP）的还原异构化反应。Dxr受到天然产品fosmidomycin和FR900098的抑制，这些化合物与DXP结合位点结合。这些化合物虽然是Dxr的强效抑制剂，但由于其极性，缺乏对结核分枝杆菌（Mtb）的全细胞活性。我们的目标是利用Mtb Dxr-fosmidomycin共晶结构设计双底物配体，以同时结合DXP和NADPH位点。这类化合物预计由于其增强的疏水性而表现出更好的全细胞活性。设计并合成了两系列化合物。两系列中的化合物均抑制Mtb Dxr。最强效的化合物（8）的IC50为17.8 µM。分析表明，化合物8通过一种新颖的非双底物机制与Mtb Dxr结合。此外，化合物8的二乙酯抑制了Mtb的生长，这使得这一类化合物成为寻找新抗结核药物的有趣领先分子。
• Leveraging the Domino Skeletal Expansion of Thia-/Selenazolidinones via Nitrogen-Atom Transfer in Hexafluoroisopropanol: Room Temperature Access to Six-Membered S/Se,N-Heterocycles
  作者：Vandana Jaiswal、Mangilal Godara、Dinabandhu Das、Vincent Gandon、Jaideep Saha

  DOI：10.1021/acs.joc.1c02621

  日期：2022.1.7

  Herein, a highly regioselective domino skeletal-expansion process that transforms 2-aminothiazolidinone into six-membered S,N-heterocycle is developed with the aid of TMS-azide in hexafluoroisopropanol (HFIP) at ambient temperature. Functioning of the C2 tertiary amine as latent reactive group on thiazolidinone moiety was the key to this development, which allowed relay substitution with azide and

  在此，在环境温度下，在六氟异丙醇 (HFIP) 中借助 TMS-叠氮化物，开发了一种高度区域选择性的多米诺骨架扩展工艺，该工艺将 2-氨基噻唑烷酮转化为六元 S，N-杂环。C2 叔胺作为噻唑烷酮部分上的潜在反应基团的功能是这一发展的关键，它允许用叠氮化物进行接力取代，并在无金属/酸的条件下进行后续的扩环。该反应还强调了从 TMS-叠氮化物到最终产物的分子间氮原子转移过程，其中不存在任何中间体叠氮噻唑烷酮。该策略可扩展到Se,N-杂环的类似合成，此外，还进行了后期药物修饰和后续转化。
• Palladium-free Sonogashira-type cross-coupling reaction of bromoisoxazolines or N-alkoxyimidoyl bromides and alkynes
  作者：N.P. Probst、B. Deprez、N. Willand

  DOI：10.1016/j.tetlet.2016.01.070

  日期：2016.3

  A Cu(I)-catalysed Sonogashira-type cross coupling reaction with aliphatic or aromatic bromoisoxazolines or N-alkoxyimidoyl bromides and alkynes is reported. The protocol we developed employs catalytic amount of copper(I), non-toxic ligand bathophenanthroline and is tolerant to a wide range of functional groups and is therefore particulary adapted in the context of drug discovery.

  据报道，Cu（I）催化的Sonogashira型交叉偶联反应与脂族或芳族溴异恶唑啉或N-烷氧基酰亚胺基溴化物和炔烃反应。我们开发的方案使用催化量的铜（I），无毒配体红菲咯啉，并且能够耐受各种官能团，因此特别适合于药物开发。